Lassen Therapeutics

About Lassen Therapeutics

Lassen Therapeutics is focused on developing novel, best-in-class biotherapeutics to improve the lives of patients suffering from serious diseases, combining innovative science, leading technology, and unmatched expertise to create life-improving medicines.

Products & Services

LASN01:An anti-IL-11 receptor antibody in development for the treatment of thyroid eye disease and idiopathic pulmonary fibrosis, currently in Phase 1 trials.

LASN500:A therapeutic in Investigational New Drug (IND) enabling studies for further development.

Pipeline:A range of breakthrough therapeutics created using industry-leading antibody technologies.

Specialties

Antibody development Fibrotic disease treatment Interleukin-11 (IL-11) targeting Thyroid eye disease treatment Idiopathic pulmonary fibrosis treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 85000000 MR: - FA: $85 million FAN: 85000000	D: 2023-12-19 FD: 2023-12-19	6 investors

Series B Latest

2023-12-19

$85.0M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Bill Bradford

MD, PhD

M

Matthias Ernst

Director of the Olivia Newton-John Cancer Research Institute and Head of the School of Cancer Medicine at La Trobe University

M

Mike Gallatin

Senior Advisor to Frazier Healthcare Partners

C

Cory Hogaboam

Professor of Medicine and Research Scientist at Cedars-Sinai; Adjunct Professor of Pathology at University of Michigan

T

Toby Maher

Professor of Clinical Medicine and Director of Interstitial Lung Disease

A

Andrew Nash

Chief Scientific Officer

View 14 more team members with Pro

Unlock Full Team Directory

Recent News